| Description | Fletikumab (NNC0109-0012) is a monoclonal antibody against IL-20 that is often used as an IL-20 inhibitor.Fletikumab is used in the study of rheumatoid arthritis and psoriasis. |
| In vitro | Fletikumab blocks IL-20 binding to the IL-20 receptor, demonstrating a potential function in inhibiting inflammation[1].IL-20 is a member of the IL-10 family, which includes IL-10, IL-19, IL-22, IL-24, IL-26, IL-28, and IL-29. It acts on renal cells and contributes to inflammation, fibrosis, and apoptosis through its receptors IL-20R1, IL-20R2, and IL-22R1[2]. |
| Synonyms | Anti-IL-20, NN-8226, NNC 0109-0012 |
| molecular weight | N/A |
| CAS | 1357158-22-5 |
| Storage | store at low temperature | store at -80°C |
| References | 1. Kragstrup TW, et al. The IL-20 Cytokine Family in Rheumatoid Arthritis and Spondyloarthritis. Front Immunol. 2018 Sep 25;9:2226. 2. Tian-Yu Lin, et al. IL-20 in Acute Kidney Injury: Role in Pathogenesis and Potential as a Therapeutic Target. Int. J. Mol. Sci. 2020, 21(3), 1009. |